In September, Valenta was a partner for regional scientific and practical conference «Infections of the Upper and Lower Respiratory Tracts — Topical Issues of Diagnostics and Treatment» organized by the Ministry of Healthcare of the Saratov region and SBEI HPE Razumovsky SMU of Saratov. Within the conference, experts presented their views on flu and ARVI prevention, including specific or nonspecific preventive measures.
Modern flu vaccines (specific preventive methods) have different ranges of effectiveness. Immunization of the population decreases flu morbidity both among immunized and not immunized individuals, and removes the risk of serious complications in immunized people. However, healthcare professionals highlight the factors that are able to influence the effectiveness of specific preventive measures: compliance of the vaccine content to the actual epidemic strains; vaccine safety; ensuring optimum immunization terms and coverage.
Nonspecific preventive methods can be divided into three components: nonspecific preventive methods targeted at the increase of organism resistibility to external adverse influences, including flu, such as toughening up, sound nutrition, etc.; hygienic activities to reduce contact with virus and thus to avoid infection; taking special medicines, though not directed at concrete viruses, but nevertheless helping to secure from getting sick.
An antiviral medicine produced by Valenta deals with the third component of nonspecific preventive measures. It suppresses virus replication and stops its dissemination in the patient’s organism. Besides, the medicine features anti-inflammatory effect suppressing production of key substances causing inflammation in tissues affected by the virus.
E.P.Lyapina, D.M.Sci, Professor, Department of Infectious Diseases at SBEI HPE Razumovsky SMU of Saratov: From October 2008 to March 2015, open clinical studies of Ingavirin effectiveness and safety were carried out. In particular, about a thousand of patients from 14 cities of Russia participated in three comparative randomized placebo controlled trials. Not a single case of a serious undesirable reaction confirmed by researchers was registered during the research. As for preventive effectiveness of Ingavirin, the comparative research proved it to exceed 60% during the preventive administering of the medicine. In total, about 6 million people have already taken Ingavirin therapy in Russia. Data of clinical studies of the medicine application for flu and ARVI treatment in adult patients, teenagers and children aged between 7 and 12 years show the decrease in the period of fever, period of intoxication (headache, weakness, dizziness) and the phenomena of respiratory tract inflammation, decrease in number of complications and the duration of disease.
The results of studies of Ingavirin therapeutic effectiveness and safety for children have helped to expand the range of applied antiviral medicines for the certain age group. Special attention should be paid to the results of double blind randomized placebo-controlled multicentre trials of Ingavirin® clinical effectiveness and safety in a daily dose of 60 mg for flu and ARVI in children aged between 7 and 12 years. On October 20, 2015, within scientific and practical symposium «Change of Paradigm of Flu Treatment: Innovations in Domestic Pediatrics» (XIV Russian Congress «Innovative Technologies in Pediatrics and Children’s Surgery»), Valenta will officially present a new form of Ingavirin for flu and ARVI to treat children aged between 7 and 12 years.